140 related articles for article (PubMed ID: 33648418)
1. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.
Atallah EL; Sadek I; Maegawa R; Cao X; Latremouille-Viau D; Pivneva I; Rossi C; Guerin A; Kota V
Leuk Lymphoma; 2021 Jul; 62(7):1730-1739. PubMed ID: 33648418
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.
Ritchie EK; Latremouille-Viau D; Guerin A; Pivneva I; Habucky K; Ndife B; Joseph GJ; Atallah EL
Leuk Lymphoma; 2019 Jun; 60(6):1476-1484. PubMed ID: 30668234
[TBL] [Abstract][Full Text] [Related]
3. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
[TBL] [Abstract][Full Text] [Related]
4. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
Robin JB; Theron A; Quittet P; Exbrayat C; Gaillard JB; Lavabre-Bertrand T; David S; Saad A; Jourdan E; Cartron G
Ann Hematol; 2022 May; 101(5):1015-1022. PubMed ID: 35278099
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
8. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H; Sandin F; Dahlén T; Dremaine A; Lübking A; Markevärn B; Myhr-Eriksson K; Olsson K; Olsson-Strömberg U; Själander A; Söderlund S; Wennström L; Wadenvik H; Stenke L; Höglund M; Richter J
Br J Haematol; 2021 Jun; 193(5):915-921. PubMed ID: 33782950
[TBL] [Abstract][Full Text] [Related]
9. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
[TBL] [Abstract][Full Text] [Related]
10. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia.
Chen Y; Xu N; Yang Y; Liu Z; Xue M; Meng L; He Q; Chen C; Zeng Q; Zhu H; Du X; Zou J; He W; Guo J; Chen S; Yuan G; Wu H; Hong M; Cheng F; Liu B; Zhang Y; Li W
Cancer Med; 2023 Aug; 12(16):17239-17252. PubMed ID: 37409506
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.
Tromp VNMF; Timmers L; Koningen L; Janssen JJWM; Westerweel PE; Geelen IGP; de Jong J; Beckeringh JJ; Boons CCLM; Hugtenburg JG
Leuk Lymphoma; 2021 Mar; 62(3):649-658. PubMed ID: 33153332
[TBL] [Abstract][Full Text] [Related]
15. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
16. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia: state-of-the-art management].
Takahashi N
Rinsho Ketsueki; 2018; 59(6):747-754. PubMed ID: 29973455
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
